Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

BCLI stock opened at $0.39 on Thursday. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $2.21. The firm has a market cap of $27.42 million, a PE ratio of -1.22 and a beta of 0.43. The business has a 50 day moving average of $0.47 and a 200-day moving average of $0.41.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. On average, research analysts expect that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC bought a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.